IR News

    2024.11.20PR information
    SymBio Presents Research Results Showing Potential Use of Intravenous Brincidofovir in Combination with Immune Checkpoint Inhibitors as a Therapy for Malignant Lymphoma at the 66th the American Society of Hematology Annual Meeting
    2024.11.05PR information
    Notice of Appointment of Executive Vice President, Corporate Officer and Global CMO
    2024.10.31Earnings Report
    Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
    2024.10.23PR information
    SymBio presents data from Phase IIa clinical trial showing clinical efficacy of IV BCV in treating symptoms of adenovirus infection
    2024.09.30Timely disclosure
    SymBio Reaches Settlement Agreement in Patent Infringement Litigation Related to TREAKISYM
    2024.08.19Timely disclosure
    SymBio Initiates Phase 1b Clinical Trial of IV Brincidofovir in Patients with Lymphoma as a First in Human Study for Oncology
    2024.08.01Earnings Report
    Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
    2024.07.12PR information
    SymBio Pharmaceuticals Announces Publication of Research Showing Antiviral Drug Brincidofovir Inhibits Infectious Viral Production of Polyomavirus
    2024.06.24PR information
    Confirmed Antitumor Effects of Brincidofovir in Peripheral T-Cell Lymphoma Suppression of the oncogenic MYC and Induction of Expression of Immunogenic Response Pathways
    2024.06.11Timely disclosure
    SymBio Announces Enrollment of the First Patient of Phase 2a Clinical Trial of Intravenous Brincidofovir for Treatment of Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
    2024.06.03PR information
    Notice of Appointment of Corporate Officer
    2024.05.13IR Materials
    株主通信「SymBio VISION vol.25」(Japanese only)
    2024.05.08Timely disclosure
    SymBio Announces Initiation of Phase 2a Clinical Trial (ATHENA) of Intravenous Brincidofovir for Treatment of Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
    2024.05.08Annual Securities Report
    四半期報告書－第20期第1四半期(2024/01/01－2024/03/31) (Japanese only)
    2024.05.07Earnings Report
    Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
    2024.05.07Timely disclosure
    Revision to Earnings Forecast for FY 2024
    2024.04.19Timely disclosure
    Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
    2024.04.19Timely disclosure
    Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
    2024.04.19IR Materials
    訂正臨時報告書(Japanese only)
    2024.04.19Timely disclosure
    Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (5th Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
    2024.04.08PR information
    Onconova Therapeutics and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc.
    2024.04.03Timely disclosure
    Notice of Confirmation of the Terms and Conditions of the New Share Issue (5th Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (5th Allotment)
    2024.04.03Timely disclosure
    Notice Regarding Adjustment of Exercise Price
    2024.04.03IR Materials
    コーポレート・ガバナンスに関する報告書 2024/04/03(Japanese only)
    2024.04.01PR information
    Notice of Personnel Changes at SymBio Pharma USA, Inc.
    2024.03.29Timely disclosure
    事業計画及び成長可能性に関する事項(Japanese only)
    2024.03.25IR Materials
    臨時報告書(Japanese only)
    2024.03.25Timely disclosure
    Notice of Shareholder Voting Results for the 19th Annual General Meeting of Shareholders
    2024.03.25Timely disclosure
    Notice of Transfer of EU Orphan Designations of Brincidofovir
    2024.03.22Timely disclosure
    Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
    2024.03.22Timely disclosure
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2024.03.22Timely disclosure
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2024.03.18PR information
    Research results showing anti-proliferative activity of brincidofovir in B-cell lymphoma to be presented at the AACR Annual Meeting 2024
    2024.03.18Timely disclosure
    Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (4th Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
    2024.02.29Timely disclosure
    Notice of Confirmation of the Terms and Conditions of the New Share Issue (4th Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (4th Allotment)
    2024.02.29Timely disclosure
    Notice Regarding Adjustment of Exercise Price
    2024.02.26IR Materials
    Notice of Convocation of the 19th Ordinary General Meeting of Shareholders
    2024.02.22Timely disclosure
    Notification of Amendment to the Articles of Incorporation
    2024.02.13PR information
    Preliminary Results of Phase 2a Clinical Trial of Intravenous Brincidofovir (IV BCV) in Immunocompromised Patients with Adenovirus Infection Selected for Oral Presentation at 50th Annual Meeting of the EBMT in Glasgow
    2024.02.09Timely disclosure
    Notice of Recognition of Impairment Loss, and Differences between Consolidated Earnings Forecasts and Actual Results for FY2023
    2024.02.08Earnings Report
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2023 [Japanese GAAP]（Consolidated）
    2024.02.07Timely disclosure
    Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (3rd Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
    2024.01.23PR information
    Preliminary Results of a Phase 2a Clinical Trial of Intravenous Brincidofovir (IV BCV) in Immunocompromised Patients with Adenovirus Infection Selected for Pediatric Best Abstracts at the 2024 Tandem Meetings of ASTCT and CIBMTR
    2024.01.22Timely disclosure
    Notice Regarding Adjustment of Exercise Price
    2024.01.22Timely disclosure
    Notice of Confirmation of the Terms and Conditions of the New Share Issue (3rd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (3rd Allotment)
    2024.01.19PR information
    SymBio Granted Patent in Japan for Use of Intravenous Brincidofovir for Treatment of Adenovirus Infection and Infectious Disease
    2024.01.10IR Materials
    株主通信「SymBio VISION vol.24」(Japanese only)
    2023.12.20Timely disclosure
    Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (2nd Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
    2023.12.11PR information
    SymBio Presents New Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
    2023.12.04Timely disclosure
    Notice of Confirmation of the Terms and Conditions of the New Share Issue (2nd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (2nd Allotment)
    2023.12.04Timely disclosure
    Notice Regarding Adjustment of Exercise Price
    2023.11.14Annual Securities Report
    四半期報告書－第19期第3四半期(2023/07/01－2023/09/30) (Japanese only)
    2023.11.14Earnings Report
    Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
    2023.11.14Timely disclosure
    Revision to Earnings Forecast and Reversal of deferred tax assets for FY 2023
    2023.11.06PR information
    SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
    2023.10.25Timely disclosure
    Notice of Confirmation of the Terms and Conditions of the New Share Issue (1st Allotment) through Third-Party Allotment based on the Agreement to Sept up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (1st Allotment)
    2023.10.25Timely disclosure
    Notice Regarding Adjustment of Exercise Price
    2023.10.16PR information
    Onconova Therapeutics announces Encouraging Rigosertib Data in RDEB-associated SCC Presented at EADV as Late Breaker
    2023.10.12PR information
    The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
    2023.10.06Timely disclosure
    Notice of Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Issue New Shares through Third-Party Allotment
    2023.08.29PR information
    Notice of Change of Global Chief Medical Officer and Appointment of Senior Vice President of SymBio Pharma USA, Inc.
    2023.08.14Timely disclosure
    Revision to Development Plan for IV Brincidofovir for BK virus
    2023.08.04Annual Securities Report
    四半期報告書－第19期第2四半期(2023/04/01－2023/06/30) (Japanese only)
    2023.08.03Earnings Report
    Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
    2023.08.03Timely disclosure
    Revision to Earnings Forecast for FY 2023
    2023.07.20Timely disclosure
    Notice of Personnel Changes at SymBio Pharma USA, Inc.
    2023.06.12PR information
    Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
    2023.06.07PR information
    Onconova Therapeutics Announces Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
    2023.05.29Timely disclosure
    IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
    2023.05.26IR Materials
    株主通信「SymBio VISION vol.23」(Japanese only)
    2023.05.10PR information
    Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
    2023.04.28Annual Securities Report
    四半期報告書－第19期第1四半期(2023/01/01－2023/03/31) (Japanese only)
    2023.04.27Earnings Report
    Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
    2023.04.24Timely disclosure
    SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
    2023.04.14Timely disclosure
    Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
    2023.04.14Timely disclosure
    Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
    2023.04.14IR Materials
    訂正臨時報告書 (Japanese only)
    2023.04.03IR Materials
    コーポレート・ガバナンスに関する報告書 2023/04/03 (Japanese only)
    2023.03.31Timely disclosure
    事業計画及び成長可能性に関する事項 (Japanese only)
    2023.03.24Timely disclosure
    Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
    2023.03.24Timely disclosure
    臨時報告書 (Japanese only)
    2023.03.24Annual Securities Report
    訂正有価証券報告書－第18期(2022/01/01－2022/12/31) (Japanese only)
    2023.03.23Timely disclosure
    Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
    2023.03.23Timely disclosure
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2023.03.23Timely disclosure
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2023.03.23IR Materials
    臨時報告書 (Japanese only)
    2023.03.23Annual Securities Report
    有価証券報告書－第18期(2022/01/01－2022/12/31) (Japanese only)
    2023.03.22Timely disclosure
    Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
    2023.03.01IR Materials
    Notice of Convocation of the 18th Ordinary General Meeting of Shareholders
    2023.02.22Timely disclosure
    Notification of Amendment to the Articles of Incorporation
    2023.02.09Earnings Report
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
    2023.02.09Timely disclosure
    Notice concerning non-operating expenses
    2022.12.26Timely disclosure
    SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
    2022.12.19Timely disclosure
    SymBio enters into Sponsored Research Agreement for non-clinical study to verify the effectiveness of brincidofovir in a virus-infected brain tissue model
    2022.12.16Timely disclosure
    SymBio files lawsuit for infringement of TREAKISYM patents
    2022.12.14Timely disclosure
    SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
    2022.12.13PR information
    Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
    2022.11.24Timely disclosure
    SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
    2022.11.08Earnings Report
    Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
    2022.11.08Timely disclosure
    Revision to Earnings Forecast for FY 2022
    2022.09.27PR information
    Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
    2022.08.31PR information
    Notice of Appointment of Corporate Officer
    2022.08.22Timely disclosure
    SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
    2022.08.09Timely disclosure
    The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
    2022.08.04Earnings Report
    Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
    2022.08.04Timely disclosure
    Revision to Earnings Forecast for FY 2022
    2022.07.11PR information
    SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
    2022.06.16PR information
    Notice of Resignation of Director
    2022.06.14Timely disclosure
    SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
    2022.06.13Timely disclosure
    SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
    2022.06.01Timely disclosure
    Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
    2022.05.18PR information
    Chimerix announces sale of brincidofovir to Emergent BioSolutions
    2022.05.16Timely disclosure
    Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
    2022.05.11Earnings Report
    Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
    2022.04.22IR Materials
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
    2022.04.22IR Materials
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
    2022.04.01Timely disclosure
    Joint research agreement with the National Cancer Center on rare cancers
    2022.03.31Timely disclosure
    Notice of Renewal of Syndicated Loan Agreement
    2022.03.30Timely disclosure
    Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
    2022.03.29Timely disclosure
    Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
    2022.03.29Timely disclosure
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2022.03.29Timely disclosure
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2022.03.08PR information
    SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
    2022.03.07Timely disclosure
    SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
    2022.02.28Timely disclosure
    SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
    2022.02.25Timely disclosure
    Response to marketing approvals of generic products
    2022.02.24Timely disclosure
    Notification of Amendments to the Articles of Incorporation
    2022.02.24Timely disclosure
    Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
    2022.02.24PR information
    SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
    2022.02.10Earnings Report
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
    2022.02.10Timely disclosure
    Notice concerning non-operating expenses
    2022.02.10Timely disclosure
    Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
    2022.01.31Timely disclosure
    Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
    2022.01.18Timely disclosure
    SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
    2022.01.06Timely disclosure
    Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
    2021.12.24
    Notice of Appointment of Executive Vice President, Corporate Officer and COO
    2021.12.20
    Notice of Appointment of Corporate Officer
    2021.11.24
    SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
    2021.11.11
    Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
    2021.11.11
    Notice Concerning Non-operating Expenses
    2021.11.11
    SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
    2021.11.11
    SymBio announces selection of "Growth Market" as new market segment
    2021.11.11
    Message from President of SymBio Pharma USA
    2021.10.12
    SymBio announces commencement of operations of SymBio Pharma USA, Inc.
    2021.09.29
    SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
    2021.09.27
    Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
    2021.09.21
    Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
    2021.09.08
    SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
    2021.09.01
    SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
    2021.08.17
    SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
    2021.08.04
    Analyst Report[Update report] (Shared Research)
    2021.08.04
    Notice Concerning Non-operating Expenses
    2021.08.04
    Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
    2021.08.02
    Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
    2021.07.15
    Notice of Appointment of Corporate Officer
    2021.07.15
    Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
    2021.06.29
    Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
    2021.06.23
    Notice of Changes of Director
    2021.06.18
    Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
    2021.06.07
    Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
    2021.05.25
    New Patent Issued in Japan for Antiviral Agent Brincidofovir
    2021.05.21
    Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
    2021.05.19
    Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
    2021.05.13
    Notice of Appointment of Corporate Officer
    2021.05.13
    Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
    2021.05.10
    SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration
    2021.04.28
    SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
    2021.04.28
    SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
    2021.04.26
    U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
    2021.04.26
    Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
    2021.04.23
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2021.04.23
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2021.03.29
    SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
    2021.03.25
    Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
    2021.03.25
    SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
    2021.03.25
    SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
    2021.03.24
    Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
    2021.03.24
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2021.03.24
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2021.03.23
    SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
    2021.03.23
    SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
    2021.03.11
    SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
    2021.02.26
    Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
    2021.02.25
    Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
    2021.02.22
    Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    2021.02.04
    3 Year Mid-Range Plan: FY 2021 to FY 2023
    2021.02.04
    Notice Concerning Non-Operating Income
    2021.02.04
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
    2021.01.28
    Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
    2021.01.12
    Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
    2020.12.23
    Notice of Appointment of Corporate Officer
    2020.12.22
    Notice of Conclusion of Syndicated Loan Agreement
    2020.12.18
    Completion, Monthly Exercise Status and Large Volume Exercise of the 51th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.12.10
    Commencement of in-house sales of the anti-cancer agent Treakisym
    2020.12.08
    Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
    2020.12.03
    Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.12.01
    Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.11.26
    Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.11.24
    National Health Insurance (NHI) Price Listing and Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
    2020.11.11
    Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.11.10
    Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
    2020.11.10
    Notice Concerning Non-operating Expenses
    2020.11.06
    Chimerix Completed Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox
    2020.11.02
    Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.10.13
    Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights
    2020.09.23
    SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation
    2020.09.17
    Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022)
    2020.09.09
    Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation
    2020.09.07
    Preparation for Sales & Marketing by SymBio's Own Sales Organization
    2020.09.01
    Final Arbitration Award in Dispute against The Medicines Company
    2020.08.25
    Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial for Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    2020.08.05
    Arbitration Award in Dispute against The Medicines Company
    2020.08.05
    Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
    2020.08.05
    Notice Concerning Non-operating Expenses
    2020.08.05
    SymBio Announces Global Development Plan of Anti-viral Drug Brincidofovir IV For Adenovirus Infectious DiseaseAfter Hematopoietic Stem Cell Transplantation
    2020.07.30
    Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
    2020.07.28
    Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
    2020.07.13
    SymBio submits Partial Change Application for use of TREAKISYM in combination with polatuzumab vedotin and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
    2020.07.09
    Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
    2020.06.23
    Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
    2020.06.01
    Completion, Monthly Exercise Status and Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.06.01
    Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.05.15
    The 25th Congress of the European Hematology Association (25th EHA Annual Congress) Accepts Abstract for Phase III Clinical Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma for Publication
    2020.05.11
    SymBio submits Partial Change Application for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
    2020.05.11
    Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.05.08
    Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.05.07
    Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.05.01
    Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.04.30
    Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
    2020.04.30
    Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.04.24
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
    2020.04.24
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
    2020.04.22
    Notice of Change (Retirement) of Director
    2020.04.21
    Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.04.14
    Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.04.01
    Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.03.27
    Notice of Shareholder Voting Results for the 15th Ordinary General Meeting of Shareholders
    2020.03.26
    Notice of Members of the Board of Director, Substitute Member of the Audit & Supervisory Board and Corporate Officers Appointment
    2020.03.26
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2020.03.26
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2020.03.25
    Completion of Patient Enrollment in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
    2020.03.25
    Onconova Announces Completion of Enrollment in Phase 3 INSPIRE Trial of IV Rigosertib
    2020.03.16
    Completion of Payment for Subscription for the 50th and 51st Stock Acquisition Rights (with Exercise Price Revision Clauses)
    2020.02.27
    Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)
    2020.02.27
    Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
    2020.02.12
    Completion, Monthly Exercise Status and Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.02.06
    3 Year Mid-Range Plan: FY 2020 to FY 2022
    2020.02.06
    Notice Concerning Non-operating Expenses
    2020.02.06
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2019[Japanese GAAP] (Non-consolidated)
    2020.02.03
    Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.01.15
    Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2020.01.06
    Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.12.19
    Notice of Appointment of Corporate Officer
    2019.12.19
    Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.12.17
    Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.12.10
    Onconova Announces Data from the INSPIRE Trial and Updated Oral Rigosertib Data at the American Society of Hematology (ASH) 2019 Annual Meeting
    2019.12.09
    Onconova Announces Collaboration with Inceptua for Pre-approval Access to Anti-cancer Drug Rigosertib
    2019.12.02
    Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.11.27
    Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.11.25
    Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.11.12
    Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement
    2019.11.08
    Summary of Financial Statements for the first nine months of fiscal year ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
    2019.11.08
    Notice Concerning Non-operating Expenses
    2019.11.08
    Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2019 ASH Annual Meeting & Exposition
    2019.11.05
    SymBio Announces Achievement of Primary Endpoint (Overall Response Rate) in Phase 3 Clinical Trial of TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
    2019.10.25
    Onconova Provides Update on the Global Phase 3 INSPIRE Trial of Rigosertib in Myelodysplastic Syndromes and on Future Clinical Trial Plans
    2019.10.18
    Notice Regarding Inappropriate Conduct of Clinical Trial Monitor
    2019.10.01
    SymBio Announces Exclusive Global License Agreement with Chimerix for Antiviral Drug, Brincidofovir
    2019.09.26
    SymBio Submits New Drug Application for TREAKISYM Ready-To-Dilute (RTD) Formulation
    2019.09.18
    Progress (LPLV) of Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
    2019.08.07
    Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022)
    2019.08.07
    Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
    2019.08.07
    Notice Concerning Non-operating Expenses
    2019.07.19
    Notice Regarding Sale of Fractional Shares Due to Reverse Stock Split
    2019.06.17
    Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.06.13
    Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.06.12
    Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer
    2019.06.11
    Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.06.03
    Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.05.28
    Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.05.22
    Launch of "Regenerative Medicine" Products that can be used with the anti-cancer drug TREAKISYM as a pretreatment agent
    2019.05.14
    Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
    2019.05.14
    Notice Concerning Non-operating Expenses
    2019.05.07
    Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.04.22
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2019.04.22
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2019.04.18
    Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.04.12
    Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.04.10
    Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.04.10
    First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
    2019.04.08
    Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
    2019.04.01
    Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.04.01
    Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib
    2019.03.29
    Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders
    2019.03.28
    Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
    2019.03.28
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2019.03.28
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2019.03.28
    Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
    2019.03.26
    TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy
    2019.03.14
    Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2019.03.05
    (Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
    2019.02.28
    Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation
    2019.02.28
    Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
    2019.02.07
    SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years)
    2019.02.07
    Notice Concerning Non-operating Expenses
    2019.02.07
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated)
    2018.12.20
    Shipments of the 25mg Presentation of Anti-cancer Drug TREAKISYM Intravenous Infusion Paused and Shipment of Substitute
    2018.12.17
    Completion of Exercise of the 39th Stock Acquisition Rights Issued by way of Third Party Allotment
    2018.12.04
    Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting
    2018.11.30
    Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation)
    2018.11.09
    Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
    2018.11.06
    Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2018 ASH Annual Meeting & Exposition
    2018.10.17
    Onconova Announces Issuance of a New U.S. Patent for Rigosertib
    2018.10.16
    SymBio Begins Preparation for Own Sales Organization for the Anti-Cancer Agent TREAKISYM
    2018.10.01
    Completion and Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.10.01
    Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.09.27
    SymBio files Partial Change Application for use of TREAKISYM as a Pretreatment to Regenerative Medical Products
    2018.09.25
    Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.09.05
    Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.09.03
    Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.08.29
    Launch of New Anti-CD20 Antibodies that can be used in combination with the anti-cancer agent TREAKISYM
    2018.08.29
    Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.08.07
    Notice Concerning Non-operating Expenses
    2018.08.07
    Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
    2018.08.01
    Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.07.30
    Revised Medical Practice Guidelines 2018 for Healthcare Professionals
    2018.07.25
    Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.07.09
    Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S.
    2018.07.04
    Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.07.02
    TREAKISYM Receives Approval for Combined Use with Anti-CD20 Antibodies
    2018.07.02
    Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.06.18
    Eagle Announces U.S. Court Decision Granting Orphan Drug Exclusivity for Bendamustine Hydrochloride Injection in the U.S.
    2018.06.06
    Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.06.01
    Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.05.28
    First Patient Enrolled in Phase 1 Clinical Trial for Oral TREAKISYM for Progressive Solid Tumors
    2018.05.18
    TREAKISYM Sales Forecast for FY2018
    2018.05.10
    Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
    2018.05.10
    Notice Concerning Non-operating Expenses
    2018.05.10
    Initiation of Collaborative Research with Keio University on TREAKISYM for Systemic Lupus Erythematosus
    2018.05.01
    Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
    2018.04.26
    (Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2018.04.26
    (Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2018.04.26
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2018.04.26
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2018.04.25
    Completion of Payment for Subscription for the 45th through 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
    2018.04.18
    TREAKISYM Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma
    2018.04.09
    Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement
    2018.03.30
    Notice of Shareholder Voting Results for the 13th Ordinary General Meeting of Shareholders
    2018.03.29
    Notice Concerning the Issuance of Stock Acquisition Rights to Directors
    2018.03.29
    Notice Concerning the Issuance of Stock Acquisition Rights to Employees
    2018.03.29
    Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
    2018.03.06
    Notice concerning Nominations for the Board of Directors/the Audit & Supervisory Board/and Substitute Member for the Audit & Supervisory Board
    2018.02.19
    Analyst Report[Basic Report]: Fair Research updates the report
    2018.02.09
    Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501"
    2018.02.07
    SymBio's Mid-Range Plan: FY2018 to FY2021
    2018.02.07
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated)
    2018.02.07
    Notice Concerning Non-Operating Income
    2018.01.22
    Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
    2018.01.18
    Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis
    2017.11.30
    Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company
    2017.11.13
    Initiation of an Arbitration against The Medicines Company
    2017.11.10
    Notice Concerning Non-operating Income
    2017.11.10
    Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated)
    2017.11.02
    Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting
    2017.10.10
    Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
    2017.09.21
    Notice of Revision to the Earnings Forecast for FY2017
    2017.09.21
    Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
    2017.08.31
    Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
    2017.08.30
    Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
    2017.08.25
    Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
    2017.08.09
    Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
    2017.08.09
    Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
    2017.08.03
    Notice Concerning Non-operating Income
    2017.08.03
    Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
    2017.07.26
    Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies"
    2017.06.30
    Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
    2017.06.05
    SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501"
    2017.05.11
    Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
    2017.05.11
    Notice Concerning Non-operating Expenses
    2017.05.11
    Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
    2017.04.24
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2017.04.24
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2017.03.30
    Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders
    2017.03.29
    Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
    2017.03.29
    Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
    2017.03.29
    Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers
    2017.02.24
    Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates
    2017.02.24
    Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment
    2017.02.09
    SymBio's Mid-Range Plan: FY2017 to FY2019
    2017.02.09
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated)
    2017.02.09
    Notice Concerning Non-Operating Income
    2017.02.01
    Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
    2016.12.19
    Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
    2016.12.06
    Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting
    2016.11.22
    Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
    2016.11.14
    Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting
    2016.11.11
    Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
    2016.11.11
    Notice concerning Non-operating Expenses
    2016.10.03
    Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders
    2016.09.28
    Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg
    2016.09.27
    Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes
    2016.09.15
    Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
    2016.09.15
    Notice concerning Partial Amendment to the Articles of Incorporation
    2016.08.26
    Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia
    2016.08.04
    Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
    2016.08.04
    Notice Concerning Non-operating Expenses
    2016.07.19
    Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)
    2016.06.16
    Corporate governance policies
    2016.06.14
    Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
    2016.06.13
    Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
    2016.06.08
    Notice concerning the Change of Major Shareholder
    2016.06.07
    Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting
    2016.06.02
    Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting
    2016.05.30
    Notice concerning the Change of Major Shareholder
    2016.05.24
    Notice concerning the Change of Major Shareholder
    2016.05.20
    Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor
    2016.05.19
    Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders
    2016.05.11
    SymBio Announces Incorporation of its U.S. Subsidiary
    2016.05.10
    Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
    2016.05.10
    Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
    2016.05.10
    Notice Concerning Non-operating Expenses
    2016.04.22
    Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
    2016.04.14
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2016.04.14
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2016.04.06
    Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
    2016.03.31
    (Correction) Notice concerning partial correction to the "Notice of Appointment of Directors"
    2016.03.31
    Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders
    2016.03.30
    Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
    2016.03.30
    Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
    2016.03.30
    Notice of Appointment of Directors
    2016.03.10
    Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates
    2016.03.10
    Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS
    2016.02.10
    SymBio's Long Range Plan: FY2016 to FY2018
    2016.02.10
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
    2016.02.10
    Notice Concerning Non-operating Expenses
    2016.02.08
    SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
    2016.02.04
    Assessment Status of Bendamustine in Europe
    2015.12.28
    SymBio starts Global Phase 3 Trial for IV Rigosertib
    2015.12.24
    SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL
    2015.12.24
    SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication)
    2015.12.24
    SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength)
    2015.12.08
    Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
    2015.12.08
    Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib
    2015.12.07
    Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
    2015.11.24
    SymBio Partner Announces European Approval of IONSYS®
    2015.11.06
    Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
    2015.11.06
    Notice Concerning Non-operating Expenses
    2015.10.30
    Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS
    2015.10.19
    Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia
    2015.10.19
    SymBio to Participate in Global Phase 3 Trial for IV Rigosertib
    2015.10.05
    SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan.
    2015.08.28
    Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
    2015.08.17
    Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
    2015.08.17
    Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
    2015.08.05
    Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
    2015.08.05
    Notice Concerning Non-operating income
    2015.06.26
    Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS
    2015.05.07
    Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
    2015.05.07
    Notice Concerning Non-operating Expense
    2015.04.10
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2015.04.10
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2015.03.27
    Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders
    2015.03.26
    Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
    2015.03.26
    Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
    2015.03.26
    Notice of Director and Auditor Appointments
    2015.03.18
    Notice Concerning Change in Status of Major shareholder
    2015.03.05
    Notice of Nomination of Director Candidates and Auditor Candidates
    2015.02.10
    SymBio's Long Range Plan: FY2015 to FY2017
    2015.02.10
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2014[Japanese GAAP] (Non-consolidated)
    2015.02.10
    Notice Concerning Non-Operating Income
    2015.02.03
    Onconova Announces its Clinical Development Plan for Rigosertib in MDS
    2015.01.26
    Establishment of Sponsored ADR (American Depositary Receipt) Program
    2015.01.13
    SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program
    2015.01.13
    Completion of Patient Enrollment of rigosertib (SyB L-1101, IV) Phase I Trial in Patient with refractory or relapsed myelodysplastic syndrome (MDS)
    2014.12.24
    Notice of Revision of the Long Range Plan: FY2014 to FY2016
    2014.12.24
    SymBio's Long Range Plan: FY2014 to FY2016 (Revised Version)
    2014.12.01
    Completion of Payment for Subscription of the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
    2014.11.14
    Notice of the Subscription for the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
    2014.11.13
    Notice of Revision of the Financial Forecast for FY2014
    2014.11.07
    Notice Concerning Non-Operation Income
    2014.11.07
    Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
    2014.11.06
    Completion of Patient Enrollment of TREAKISYM® Phase II Trial in Patient with Chronic Lymphocytic Leukemia (CLL)
    2014.09.19
    Notice Concerning Change in Status of Major shareholder
    2014.09.18
    Notice Concerning Relocation of Head Office
    2014.08.14
    Onconova's Announcement in the Development of Rigosertib for patients with MDS in Second Quarter 2014
    2014.08.06
    Notice Concerning Non-Operation Expense
    2014.08.06
    Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
    2014.06.18
    SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine Hydrochloride (SyB L-0501)
    2014.05.08
    Notice Concerning Non-Operation Expense
    2014.05.08
    Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
    2014.04.30
    Notice Concerning Adjustment to Exercise Price of Stock Option
    2014.04.30
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
    2014.04.30
    Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
    2014.04.15
    Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
    2014.04.15
    Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
    2014.03.28
    Notice of Shareholder Voting Results for the 9th Ordinary General Meeting of Shareholders
    2014.03.27
    Notice Concerning the Appointment of Directors
    2014.03.27
    Announcement Personnel Changes
    2014.03.06
    Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors
    2014.03.06
    Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
    2014.02.20
    Onconova Announces Results from Phase 3 ONTIME Study of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)
    2014.02.20
    SymBio's Long Range Plan: FY2014 to FY2016
    2014.02.12
    Summary of Financial Statements for the Fiscal Year Ended December 31, 2013[Japanese GAAP](Non-consolidated)